Brainstorm Cell Therapeutics Inc.

AI-generated fair value estimate for this company.

Method: Liquidation/cash value approach: as of the June 30, 2026 10-Q, cash and equivalents were only $22,000 against a total stockholders' deficit of $11.6M (11,034,775 shares outstanding), leaving effectively zero residual equity value; a nominal $0.02/share is assigned for embedded optionality on the NurOwn Phase 3b ALS program.

Reasoning: BrainStorm is balance-sheet insolvent (negative equity, near-zero cash) with severe going-concern risk, so a probability-weighted pipeline NPV is not supportable; cash/liquidation value is the only defensible anchor, with a nominal residual for real but unfunded and speculative clinical optionality.